Fabio Broccatelli

机构：Acentech (United States) · ORCID：0000-0002-0724-9752

发表论文 49 篇 · 总被引 2228 次 · h-index 23

代表论文

• Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers (2022 · Nature Communications · 被引 135)
• Application of Empirical Scalars To Enable Early Prediction of Human Hepatic Clearance Using In Vitro-In Vivo Extrapolation in Drug Discovery: An Evaluation of 173 Drugs (2022 · Drug Metabolism and Disposition · 被引 37)
• PROTACs Targeting BRM (SMARCA2) Afford Selective In Vivo Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models (2024 · Journal of Medicinal Chemistry · 被引 32)
• Benchmarking Accuracy and Generalizability of Four Graph Neural Networks Using Large In Vitro ADME Datasets from Different Chemical Spaces (2022 · Molecular Informatics · 被引 32)
• Development of Liposome Systems for Enhancing the PK Properties of Bivalent PROTACs (2023 · Pharmaceutics · 被引 25)
• Optimization of a Novel DEL Hit That Binds in the Cbl-b SH2 Domain and Blocks Substrate Binding (2024 · ACS Medicinal Chemistry Letters · 被引 14)